JP2024515169A5 - - Google Patents
Info
- Publication number
- JP2024515169A5 JP2024515169A5 JP2023562501A JP2023562501A JP2024515169A5 JP 2024515169 A5 JP2024515169 A5 JP 2024515169A5 JP 2023562501 A JP2023562501 A JP 2023562501A JP 2023562501 A JP2023562501 A JP 2023562501A JP 2024515169 A5 JP2024515169 A5 JP 2024515169A5
- Authority
- JP
- Japan
Links
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163172401P | 2021-04-08 | 2021-04-08 | |
| US63/172,401 | 2021-04-08 | ||
| US202163290349P | 2021-12-16 | 2021-12-16 | |
| US63/290,349 | 2021-12-16 | ||
| PCT/US2022/023660 WO2022216815A1 (en) | 2021-04-08 | 2022-04-06 | Treatment of cancer with nk cells and a cd20 targeted antibody |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2024515169A JP2024515169A (ja) | 2024-04-05 |
| JP2024515169A5 true JP2024515169A5 (https=) | 2025-04-14 |
| JPWO2022216815A5 JPWO2022216815A5 (https=) | 2025-04-14 |
Family
ID=83546502
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023562501A Withdrawn JP2024515169A (ja) | 2021-04-08 | 2022-04-06 | Ｎｋ細胞およびｃｄ２０標的抗体を用いた癌治療 |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US20240180962A1 (https=) |
| EP (1) | EP4319769A4 (https=) |
| JP (1) | JP2024515169A (https=) |
| KR (1) | KR20240024046A (https=) |
| AU (1) | AU2022254978A1 (https=) |
| WO (1) | WO2022216815A1 (https=) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2018124766A2 (ko) | 2016-12-28 | 2018-07-05 | 주식회사 녹십자랩셀 | 키메라 항원 수용체 및 이를 발현하는 자연 살해 세포 |
| EP3633029A4 (en) | 2017-05-26 | 2021-06-09 | Green Cross Lab Cell Corporation | METHOD OF DEVELOPING A NATURAL KILLER CELL USING A T-CELL |
| US12116417B2 (en) | 2017-11-14 | 2024-10-15 | GC Cell Corporation | Anti-HER2 antibody or antigen-binding fragment thereof, and chimeric antigen receptor comprising same |
| US11649294B2 (en) | 2017-11-14 | 2023-05-16 | GC Cell Corporation | Anti-HER2 antibody or antigen-binding fragment thereof, and chimeric antigen receptor comprising same |
| MY199770A (en) | 2018-11-14 | 2023-11-22 | Green Cross Lab Cell Corp | Method for culturing cord blood-derived natural killer cells using transformed t cells |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX2017012939A (es) * | 2015-04-08 | 2018-05-22 | Novartis Ag | Terapias cd20, terapias cd22 y terapias de combinacion con una celula que expresa un receptor quimerico de antigeno (car) de cd19. |
| WO2018005973A1 (en) * | 2016-06-30 | 2018-01-04 | Nant Holdings Ip, Llc | Nant cancer vaccine |
| WO2018027135A1 (en) * | 2016-08-04 | 2018-02-08 | Unum Therapeutics Inc. | Treatment of lymphoma using antibody-coupled t cell receptor |
| WO2018124766A2 (ko) * | 2016-12-28 | 2018-07-05 | 주식회사 녹십자랩셀 | 키메라 항원 수용체 및 이를 발현하는 자연 살해 세포 |
| JP7383620B2 (ja) * | 2018-01-31 | 2023-11-20 | セルジーン コーポレイション | 養子細胞療法およびチェックポイント阻害剤を使用する併用療法 |
| EP4474391A3 (en) * | 2018-05-14 | 2025-02-26 | Indapta Therapeutics, Inc. | Subsets of human natural killer cells with enhanced antibody-directed immune responses |
| CA3205637A1 (en) * | 2020-12-17 | 2022-06-23 | Artiva Biotherapeutics, Inc. | Treatment of cancer with nk cells and a cd20 targeted antibody |
-
2022
- 2022-04-06 JP JP2023562501A patent/JP2024515169A/ja not_active Withdrawn
- 2022-04-06 WO PCT/US2022/023660 patent/WO2022216815A1/en not_active Ceased
- 2022-04-06 EP EP22785367.8A patent/EP4319769A4/en active Pending
- 2022-04-06 US US18/285,637 patent/US20240180962A1/en active Pending
- 2022-04-06 KR KR1020237038551A patent/KR20240024046A/ko not_active Withdrawn
- 2022-04-06 AU AU2022254978A patent/AU2022254978A1/en not_active Abandoned